1. Top of page
  2. Abstract
  3. Introduction
  4. Definition of multicomponent collection
  5. Multicomponent collection techniques
  6. Disclosures
  7. References

Introduction:  An increasing demand for blood components is opposed by a decreasing donor availability for the collection of the required blood components. Furthermore, current stem cell transplantation regiments require the collection of more than one similar or different component from one donor or patient. One strategy for maintaining the patients’ supply with the required blood components can be the concurrent collection of more than one component from one donor by apheresis, thus multicomponent apheresis.

Scope of multicomponent combinations:  Combinations are possible for nearly every kind of blood components. In one session it is possible – depending on the apheresis device – to collect up to four plasma units alone, one or more plasma units and one or two red blood cell (RBC) units, one or more plasma units and one or more platelet units, one or more plasma units and one or two RBC units and one or more platelet units, one or two RBC units and one or more platelet units, two RBC units alone, one or more platelet units.

Also in leucocytapheresis the collection of more than one blood component has become a routine procedure. Performing allogeneic stem cell apheresis can lead to a cell dose for two transplantations or to one unit of PBSCs and concurrently collected and frozen mononuclear cells used for donor lymphocyte infusions therapy. Autologous mononuclear cell products (e.g. PBSCs or monocytes for dendritic cell generation) usually are cryoconserved before use and require additional plasmaproteins for cryoconservation. The latter can be obtained by the concurrent collection of plasma during leucocytapheresis. Thus, the combination of cell and plasma units or of cell units of different dose or for different purpose are further examples for the implementation of multicomponent apheresis in tumor therapy.

Conclusions:  The understanding of apheresis technologies facilitates the use of multicomponent apheresis in the vast application field for tailoring the kind, quantity, and quality of blood components for patient care.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Definition of multicomponent collection
  5. Multicomponent collection techniques
  6. Disclosures
  7. References

During the last years, requirements for blood components have increased continuously for different reasons. These are for example demographic factors like an increase in the average age of the population in most European countries and thus more older patients to be treated, more aggressive surgical procedures, and more aggressive and efficient cancer therapies. This increase is illustrated in the Paul Ehrlich Institute’s “Report on notifications pursuant to Section 21 German Transfusion Act for 2007” [1] showing that from 2003 to 2007, the production of blood components increased as follows: RBC units by 7·8%, platelet (PLT) units by 31·1% and fresh frozen plasma (FFP) units by 16·1%. On the other hand, the donor population is decreasing. Based on statistical data from 2004[2] that has been confirmed in 2009 [3], Greinacher et al. projected a decrease in blood donations by 27·5–32·6 percent to be expected in 2015 in comparison with 2004 [4]. In addition, in most countries guidelines regularise a more and more restrictive donor selection for increasing the recipients’ safety. Unfortunately, these restrictions increase the donor deferral rates, too [5–7]. In addition to this rising imbalance between increasing need for blood components and decreasing donor availability, transfusion medicine services are also faced with economical pressures when providing blood components. On the one hand, costs for instruments, disposables, reagents, staff and additional donor testing rise continuously. On the other hand, financial resources in the health systems are limited so that the increase in costs cannot be passed on to the users or the reimbursement companies. For solving these problems, transfusion medicine services have been encouraged to advance the development and implementation of techniques enabling the concurrent collection of more than one single blood component during one donation from one donor, thus multicomponent collection.

Furthermore, it has been shown that cellular blood products prepared by apheresis are better standardized and often of higher quality than products prepared manually from whole blood [8–15].

Definition of multicomponent collection

  1. Top of page
  2. Abstract
  3. Introduction
  4. Definition of multicomponent collection
  5. Multicomponent collection techniques
  6. Disclosures
  7. References

Although there are definitions for multicomponent aphereses as procedures leading to at least two different blood components [16], most authors define a multicomponent apheresis as a procedure in which two or more identical or different blood components are collected [17–22]. This nomenclature will be maintained in this review.

Multicomponent collection techniques

  1. Top of page
  2. Abstract
  3. Introduction
  4. Definition of multicomponent collection
  5. Multicomponent collection techniques
  6. Disclosures
  7. References

For multicomponent collections, usually the same centrifugation techniques are used like those for the collection of each component alone. As extensive descriptions of the different apheresis systems have been provided in books and book chapters [23,24], this overview will be limited to a brief description of multicomponent collections which usually are performed automatically and in a standardized way using cell separators.

All cytapheresis systems are capable to produce up to three white cell poor platelet units either in the apheresis procedure [9–12,14,15,25–34] or through an additional filtration step [27,29–31]. Multicomponent apheresis procedures using these techniques enable the concurrent collection of up to three platelet units alone or in combination with fresh frozen plasma fulfilling all quality criteria without the need of further manipulations [21,35–39].

Furthermore, some devices are equipped with protocols for the collection of volume reduced PLT concentrates [40–44] which are not only adequate for intrauterine transfusion, but also permit the concurrent collection of larger plasma quantities.

As RBCs possess a significant higher density than plasma or platelets, they represent a distinct cellular component in the separation procedure when exposed to centrifugation force. This cell fraction can be collected alone or concurrently with PLTs and plasma [30,45–51]. The quality of the so collected PLTs and plasma is not impaired by the concurrent RBC collection, and the quality of the collected RBCs is superior to RBCs collected as whole blood donation [8,47,50–52], specifically because of the controlled mixing of the blood with the citrate and a well-defined haematocrit. The RBC apheresis techniques enable the collection of two RBC units in one procedure. On the one hand, this enlarges the flexibility in blood component production. On the other hand, the concurrent collection of two RBC units increases the risk of the donors’ iron depletion [53,54].

Besides the standard components like plasma, RBCs, and PLTs also different kinds of white blood cells (WBCs) are increasingly collected using techniques for obtaining more than one product during one procedure. As granulocytapheresis usually yields one single therapeutic dose, it shall not be discussed in this review. Other leucocytapheresis procedures, e.g. mononuclear cell collections, however, often are performed in a way to obtain more than one product. In recent years, stem cell transplantation is increasingly performed in terms of tandem transplantations [55–64]. Thus, stem cell apheresis is frequently performed with the objective of collecting two stem cell doses, thus two products within one apheresis procedure. Plasma needed for cryopreservation of the collected stem cells can be collected during the same procedure. In cases where more mononuclear cells are collected in one apheresis than required for one transplantation, the excess cells can be portioned into lymphocyte doses for further donor lymphocyte infusions.

Donor lymphocyte infusions for augmenting the graft-versus-tumor effect or for the treatment of leukemia relapse after haematopoietic stem cell transplantation is used increasingly [65–68]. These therapies usually require multiple injections of increasing numbers of mononuclear cells. Thus, lymphocytaphereses are performed in a way that results in multiple units of concentrated lymphocytes. The cells are partly diluted in concurrently collected donor plasma, portioned and cryopreserved.

The same approach is followed in the preparation of mononuclear cells for dendritic cell (DC) generation. After successful experiments in mice, manipulated DCs have been proposed as a “vaccine” to stimulate antitumor immunity [69–78]. For this therapeutical approach, important quantities of monocytes are usually required to get enough DCs for vaccination purposes. The plasma needed for the cell cultures [71] is concurrently collected with the mononuclear cells [79–83].

Thus, these collections of WBCs and plasma represent further applications of multicomponent collection.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Definition of multicomponent collection
  5. Multicomponent collection techniques
  6. Disclosures
  7. References
  • 1
    Henseler O, Heiden M, Haschberger B, Hesse J, Seitz R: [Report on notifications pursuant to Section 21 German Transfusion Act for 2007]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009; 52:715731
  • 2
    Statistisches Bundesamt: Bevölkerung Deutschlands bis 2050 – 10. koordinierten Bevölkerungsvorausberechnung für Deutschland. Wiesbaden, Statistisches Bundesamt, 2003
  • 3
    Statistisches Bundesamt: Bevölkerung Deutschlands bis 2060 – 12. koordinierten Bevölkerungsvorausberechnung für Deutschland. Wiesbaden, Statistisches Bundesamt, 2009
  • 4
    Greinacher A, Fendrich K, Alpen U, Hoffmann W: Impact of demographic changes on the blood supply: mecklenburg-West Pomerania as a model region for Europe. Transfusion 2007; 47:395401
  • 5
    Zou S, Musavi F, Notari EP, Rios JA, Trouern-Trend J, Fang CT: Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006. Transfusion 2008; 48:25312539
  • 6
    Glaser A, Zimmermann R, Zingsem J, Weisbach V, Neidhardt B, Eckstein R: Change of the deferral rate of volunteer apheresis donors by the new edition of the ‘German Guidelines for Blood Grouping and Blood Transfusion (Haemotherapy)’. Infusionsther Transfusionsmed 1999; 26:300305
  • 7
    Custer B, Chinn A, Hirschler Nora V, Busch Michael P, Murphy Edward L: The consequences of temporary deferral on future whole blood donation. Transfusion 2007; 47:15141523
  • 8
    Matthes G, Tofote U, Krause KP, Pawlow I, Kucera W, Lerche D: Improved red cell quality after erythroplasmapheresis with MCS-3P. J Clin Apher 1994; 9:183188
  • 9
    Fournel JJ, Zingsem J, Riggert J, Muylle L, Müller N, Kohler M, Beaumont JL, Baeten M, Eckstein R, Van Waeg G: A multicenter evaluation of the routine use of a new white cell-reduction apheresis system for collection of platelets. Transfusion 1997; 37:487492
  • 10
    Zingsem J, Zimmermann R, Weisbach V, Glaser A, Van Waeg G, Eckstein R: Comparison of COBE white cell-reduction and standard plateletpheresis protocols in the same donors. Transfusion 1997; 37:10451049
  • 11
    Zingsem J, Glaser A, Weisbach V, Zimmermann R, Neidhardt B, Van Waeg G, Eckstein R: Evaluation of a platelet apheresis technique for the preparation of leukocyte-reduced platelet concentrates. Vox Sang 1998; 74:189192
  • 12
    Zingsem J, Zimmermann R, Weisbach V, Glaser A, Bunkens H, Eckstein R: Comparison of a new WBC-reduction system and the standard plateletpheresis protocol in the same donors. Transfusion 2001; 41:396400
  • 13
    Zeiler TA, Kretschmer V: Automated blood component collection with the MCS 3p cell separator: evaluation of three protocols for buffy coat-poor and white cell-reduced packed red cells and plasma. Transfusion 1997; 37:791797
  • 14
    Zeiler T, Zingsem J, Moog R, Kretschmer V, Eckstein R, Müller N, Eisenbeisz F: Periodic alternating interface positioning to lower WBC contamination of apheresis platelet concentrates: a multicenter evaluation. Transfusion 2000; 40:687692
  • 15
    Moog R, Zeiler T, Heuft HG, Stephan B, Fischer EG, Kretschmer V, Rodel-Spieker R, Strasser S, Zingsem J: Collection of WBC-reduced single-donor PLT concentrates with a new blood cell separator: results of a multicenter study. Transfusion 2003; 43:11071114
  • 16
    Coffe C: [Multiple apheresis]. Transfus Clin Biol 2007; 14:8689
  • 17
    Matthes G, Moog R, Radtke H, Wiesneth M, Zingsem J: Implementation of Preparative Haemaphereses in the Production of Blood-Derived Cell Concentrates Recommendations for Preparative Haemapheresis of the German Society of Transfusion Medicine and Immunohaematology (DGTI). Transfus Med Hemother 2007; 34:367374
  • 18
    Valbonesi M, Florio G, Ruzzenenti MR, Bo A, Bruni R, Giannini G, Morelli F: Multicomponent collection (MCC) with the latest hemapheresis apparatuses. Int J Artif Organs 1999; 22:511515
  • 19
    Popovsky MA: Multicomponent apheresis blood collection in the United States: current status and future directions. Transfus Apher Sci 2005; 32:299304
  • 20
    Blanco L: Tailored collection of multicomponent by apheresis. Transfus Apher Sci 2002; 27:123127
  • 21
    Valbonesi M, Giannini G, Morelli F, Frisoni R, Capra C: Multicomponent collection as of 2005. Transfus Apher Sci 2005; 32:287297
  • 22
    Yuan S, Gornbein J, Smeltzer B, Ziman AF, Lu Q, Goldfinger D: Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections. Transfusion 2008; 48:12131219
  • 23
    Zingsem J: Die Optimierung von Thrombozytaphereseverfahren zur Herstellung wirkstoffdefinierter Blutprodukte. München: Hut; 2007.
  • 24
    Burgstaler EA: Current instrumentation for apheresis. McLeodBC, (ed) Apheresis: Principles and Practice, 2nd ed. Bethesda, AABB Press, 2003: p. 95130.
  • 25
    Zingsem J, Strasser E, Ringwald J, Zimmermann R, Weisbach V, Eckstein R: Evaluation of a new apheresis system for the collection of leukoreduced single-donor platelets. Transfusion 2007; 47:987994
  • 26
    Burgstaler EA, Winters JL, Pineda AA: Paired comparison of Gambro Trima Accel versus Baxter Amicus single-needle plateletpheresis. Transfusion 2004; 44:16121620
  • 27
    Moog R, Müller N: White cell reduction during plateletpheresis: a comparison of three blood cell separators. Transfusion 1999; 39:572577
  • 28
    Moog R, Müller N, Goergens D: Platelet collection with the Amicus and the AS.TEC 204 blood cell separators. Transfusion 1998; 38:285289
  • 29
    Moog R: Fuji surge technique and continuous in-line filtration to improve the quality of single donor platelet concentrates. J Clin Apher 2002; 17:199203
  • 30
    Moog R, Bartsch R, Müller N: Concurrent collection of in-line filtered platelets and red blood cells by apheresis. Ann Hematol 2002; 81:322325
  • 31
    Burgstaler EA, Pineda AA, Wollan P: Plateletapheresis: comparison of processing times, platelet yields, and white blood cell content with several commonly used systems. J Clin Apher 1997; 12:170178
  • 32
    Ringwald J, Zingsem J, Zimmermann R, Strasser E, Antoon M, Eckstein R: First comparison of productivity and citrate donor load between the Trima version 4 (dual-stage filler) and the Trima Accel (single-stage filler) in the same donors. Vox Sang 2003; 85:267275
  • 33
    Valbonesi M, De Luigi MC, Florio G, Giannini G, Bruni R, Fabi L, Spina G: The Cobe Trima system as a tool for optimizing component collection. A further step towards total apheresis. Int J Artif Organs 1999; 22:5859
  • 34
    Picker SM, Radojska SM, Gathof BS: Prospective comparison of high-dose plateletpheresis with the latest apheresis systems on the same donors. Transfusion 2006; 46:16011608
  • 35
    Burgstaler EA, Pineda AA, Bryant SC: Prospective comparison of plateletapheresis using four apheresis systems on the same donors. J Clin Apher 1999; 14:163170
  • 36
    Heuft HG, Moog R, Fischer E, Zingsem J: Donor Safety and Tolerance in Triple Platelet Aphereses. Final Results from 2.254 Aphereses of the DGTI Hemapheresis Multicenter Trial. Transfus Med Hemother 2008; 35:40
  • 37
    Zingsem J, Weisbach V, Zimmermann R, Glaser A, Bunkens H, Eckstein R: Preparation of FFP as a by-product of plateletpheresis. Transfusion 2002; 42:8186
  • 38
    Valbonesi M, Bruni R, Florio G, Zanella A, Bunkens H: Cellular contamination of plasma collected with various apheresis systems. Transfus Apher Sci 2001; 24:9194
  • 39
    Tynngard N, Lindahl TL, Trinks M, Studer M, Berlin G: The quality of platelet concentrates produced by COBE Spectra and Trima Accel cell separators during storage for 7 days as assessed by in vitro methods. Transfusion 2008; 48:715722
  • 40
    Ringwald J, Schroth M, Faschingbauer F, Strobel J, Strasser E, Schild RL, Goecke TW: Intrauterine use of hyperconcentrated platelet concentrates collected with Trima Accel in a case of neonatal alloimmune thrombocytopenia. Transfusion 2007; 47:14881493
  • 41
    Ringwald J, Duerler T, Frankow O, Zimmermann R, Zingsem J, Strasser E, Antoon M, Eckstein R: Collection of hyperconcentrated platelets with Trima Accel. Vox Sang 2006; 90:9296
  • 42
    Ringwald J, Walz S, Zimmermann R, Zingsem J, Strasser E, Weisbach V, Eckstein R: Hyperconcentrated platelets stored in additive solution: aspects on productivity and in vitro quality. Vox Sang 2005; 89:1118
  • 43
    Perseghin P, Mascaretti L, Speranza T, Belotti D, Baldini V, Dassi M, Riva M, Pogliani EM, Sciorelli G: Platelet activation during plasma-reduced multicomponent PLT collection: a comparison between COBE Trima and Spectra LRS turbo cell separators. Transfusion 2004; 44:125130
  • 44
    Dumont LJ, Krailadsiri P, Seghatchian J, Taylor LA, Howell CA, Murphy MF: Preparation and storage characteristics of white cell-reducedhigh-concentration platelet concentrates collected by anapheresis system for transfusions in utero. Transfusion 2000; 40:91100
  • 45
    Elfath MD, Whitley P, Jacobson MS, Cranfill-Hupp K, Kemp DM, McNeil D, Sawyer S, Bell-Dize S, Gorlin JB, Kevy SV, McAteer MJ: Evaluation of an automated system for the collection of packed RBCs, platelets, and plasma. Transfusion 2000; 40:12141222
  • 46
    Holme S, Elfath MD, Whitley P: Evaluation of in vivo and in vitro quality of apheresis-collected RBC stored for 42 days. Vox Sang 1998; 75:212217
  • 47
    Leitner GC, Jilma-Stohlawetz P, Stiegler G, Weigel G, Horvath M, Tanzmann A, Hocker P, Fischer MB: Quality of packed red blood cells and platelet concentrates collected by multicomponent collection using the MCS plus device. J Clin Apher 2003; 18:2125
  • 48
    Menichella G, Serafini R, Ciarli M, Paladini U, Pierelli L, Bunkens H, Leone G: A new blood donation strategy: automated blood collection (ABC). Int J Artif Organs 2001; 24:173177
  • 49
    Moog R, Franck V, Pierce JA, Müller N: Evaluation of a concurrent multicomponent collection system for the collection and storage of WBC-reduced RBC apheresis concentrates. Transfusion 2001; 41:11591164
  • 50
    Picker SM, Radojska SM, Gathof BS: Evaluation of concurrent collection of in-line filtered platelets and packed red blood cells by multicomponent apheresis with three last-generation apparatuses. Vox Sang 2006; 91:4755
  • 51
    Picker SM, Radojska SM, Gathof BS: Prospective evaluation of double RBC collection using three different apheresis systems. Transfus Apher Sci 2006; 35:197205
  • 52
    Picker SM, Radojska SM, Gathof BS: In vitro quality of red blood cells (RBCs) collected by multicomponent apheresis compared to manually collected RBCs during 49 days of storage. Transfusion 2007; 47:687696
  • 53
    Högler W, Mayer W, Messmer C, Eibl G, Innerhofer P, Schonitzer D, Nussbaumer W: Prolonged iron depletion after allogeneic 2-unit RBC apheresis. Transfusion 2001; 41:602605
  • 54
    Radtke H, Mayer B, Rocker L, Salama A, Kiesewetter H: Iron supplementation and 2-unit red blood cell apheresis: a randomized, double-blind, placebo-controlled study. Transfusion 2004; 44:14631467
  • 55
    Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101:100106
  • 56
    Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, Somlo G: Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res 2009; 29:32813288
  • 57
    Whitman SP, Ruppert AS, Marcucci G, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, Larson RA, Caligiuri MA, Bloomfield CD: Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 2007; 109:51645167
  • 58
    Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, Gahrton G: Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004; 22:16741681
  • 59
    Arfons LM, Tomblyn M, Rocha V, Lazarus HM: Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol 2009; 16:112123
  • 60
    Ayas M, Al-Jefri A, Al-Seraihi A, Al-Mahr M, Ai-Ahmari A, El-Solh H: Second stem cell transplantation in patients with Fanconi anemia using Antithymocyte globulin alone for conditioning. Biol Blood Marrow Transplant 2008; 14:445448
  • 61
    Shah AJ, Kapoor N, Weinberg KI, Crooks GM, Kohn DB, Lenarsky C, Kaufman F, Epport K, Wilson K, Parkman R: Second hematopoietic stem cell transplantation in pediatric patients: overall survival and long-term follow-up. Biol Blood Marrow Transplant 2002; 8:221228
  • 62
    Hosing C, De Lima M, Saliba RM, Shahjahan M, Couriel D, Andersson B, Giralt S, Champlin RE: Second allogeneic hematopoietic stem cell transplantation (HSCT) in patients with refractory hematological malignancies. Blood 2002; 100:1666
  • 63
    Schechter T, Avila L, Dupuis LL, Pollock-BarZiv S, Gassas A, Finkelstein Y, Armstrong C, Doyle JJ: Outcomes of Second Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Children. Blood 2008; 112:1119
  • 64
    Ruutu T, Brand R, Van Biezen A, Rocha V, Sureda A, Tichelli A, Einsele H, Dini G, Bregni M, Garderet L, Apperley J, Gratwohl A, Niederwieser D, De Witte T: Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse of Malignant Disease: retrospective Analysis of Outcome and Predictive Factors. Blood 2008; 112:132
  • 65
    Tomblyn M, Lazarus HM: Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant 2008; 42:569579
  • 66
    Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, Volin L, Gurman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V: Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25:49384945
  • 67
    Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs KS, Mackinnon S: High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14:5058
  • 68
    Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W: Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92:414417
  • 69
    Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, Von Den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:16691678
  • 70
    Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223:115
  • 71
    Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B: Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 2002; 268:131140
  • 72
    Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195:12791288
  • 73
    Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J: Building on dendritic cell subsets to improve cancer vaccines. Curr Opin Immunol 2010; 22:25863
  • 74
    Um SJ, Choi YJ, Shin HJ, Son CH, Park YS, Roh MS, Kim YS, Kim YD, Lee SK, Jung MH, Lee MK, Son C, Choi PJ, Chung J, Kang CD, Lee EY: Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer. 2010. in press, [Epub ahead of print]
  • 75
    Ardon H, Van GoolS, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 2010. (DOI: 10.1007/s11060-010-0131-y; Online first) [Epub ahead of print]
  • 76
    Kim W, Liau LM: Dendritic cell vaccines for brain tumors. Neurosurg Clin N Am 2010; 21:139157
  • 77
    Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 2007; 449:419426
  • 78
    Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138147
  • 79
    Glaser A, Schuler-Thurner B, Feuerstein B, Zingsem J, Zimmermann R, Weisbach V, Eckstein R: Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma. Transfusion 2001; 41:117122
  • 80
    Strasser EF, Berger TG, Weisbach V, Zimmermann R, Ringwald J, Schuler-Thurner B, Zingsem J, Eckstein R: Comparison of two apheresis systems for the collection of CD14 +  cells intended to be used in dendritic cell culture. Transfusion 2003; 43:13091316
  • 81
    Strasser EF, Dittrich S, Weisbach V, Zimmermann R, Ringwald J, Achenbach S, Zingsem J, Eckstein R: Comparison of two mononuclear cell program settings on two apheresis devices intended to collect high yields of CD14 +  and CD3 +  cells. Transfusion 2004; 44:11041111
  • 82
    Strasser EF, Eckstein R: Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. Transfus Med Rev 2010; 24:130139
  • 83
    Strasser EF, Schremmer M, Hendelmeier M, Weiss D, Ringwald J, Zimmermann R, Weisbach V, Zingsem J, Eckstein R: Automated CD14+ monocyte collection with the autoMNC program of the COM.TEC cell separator. Transfusion 2007; 47:22972304